How many drugs treat Streptococcal meningitis?

Drug Landscape tracks 9 marketed treatments for Streptococcal meningitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/streptococcal-meningitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Streptococcal meningitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Streptococcal meningitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcal meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Chlorocidin	CHLORAMPHENICOL	Parkedale	Amphenicol-class Antibacterial	Cytochrome P450 3A4	1950-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Merrem	Merrem	National Institutes of Health Clinical Center (CC)		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Streptococcal meningitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Streptococcal meningitis
GSK · 1 drug in Streptococcal meningitis
Generic (originally Roche) · 1 drug in Streptococcal meningitis
Karlstad University · 1 drug in Streptococcal meningitis
National Institutes of Health Clinical Center (CC) · 1 drug in Streptococcal meningitis
Parkedale · 1 drug in Streptococcal meningitis
· 1 drug in Streptococcal meningitis
Sterimax · 1 drug in Streptococcal meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcal meningitis:

Cite this brief

Drug Landscape (2026). Streptococcal meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcal-meningitis. Accessed 2026-06-10.

Streptococcal meningitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing